Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 9.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 68,643 shares of the company’s stock after selling 7,192 shares during the period. Northwest & Ethical Investments L.P.’s holdings in Denali Therapeutics were worth $2,000,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Denali Therapeutics by 879.5% during the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after purchasing an additional 1,847 shares in the last quarter. CWM LLC lifted its stake in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares in the last quarter. Quest Partners LLC acquired a new position in Denali Therapeutics during the third quarter worth $73,000. Assetmark Inc. lifted its stake in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $25.00 on Friday. The firm has a market capitalization of $3.60 billion, a PE ratio of -9.06 and a beta of 1.40. The business’s fifty day moving average price is $27.41 and its 200 day moving average price is $24.43. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the firm earned ($0.72) earnings per share. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.69 EPS for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the transaction, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This represents a 14.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the transaction, the director now owns 111,056 shares of the company’s stock, valued at $3,331,680. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock valued at $2,474,440 over the last quarter. 7.90% of the stock is owned by insiders.

Analyst Ratings Changes

DNLI has been the topic of a number of research reports. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Jefferies Financial Group upped their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Citigroup upped their price objective on Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Bank of America upped their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.